admin – Page 8046 – Get News Story

Ischemic Stroke Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Biogen, Athersys, Inc., Tarveda Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ischemic Stroke pipeline constitutes 50+ key companies continuously working towards developing 55+ Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Ischemic Stroke Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.

Some of the key takeaways from the Ischemic Stroke Pipeline Report:

Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years.
Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment

Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.
In July 2022, ACTICOR BIOTECH disclosed that its drug candidate, glenzocimab, obtained “PRIority Medicines” designation from the European Medicines Agency (EMA) for treating stroke patients. This designation facilitates Acticor Biotech in enhancing engagements and securing preliminary discussions with regulatory bodies to solidify the clinical development strategy for glenzocimab in stroke treatment.
In July 2022, NervGen Pharma revealed that a groundbreaking preclinical study conducted by the University of Cincinnati and Case Western Reserve University (CWRU) has been published in the scientific journal Cell Reports. This study showcases the effectiveness of NervGen’s unique drug, NVG-291-R, in facilitating nervous system repair and notable functional recuperation in a mouse model of severe ischemic stroke. Notably, the treatment demonstrated significant recovery benefits even when initiated up to 7 days after the onset of the stroke.
In June 2022, Pharmazz Inc has unveiled encouraging top-line outcomes from its Phase III clinical trial assessing sovateltide’s efficacy in treating acute ischemic stroke. The results highlighted a notable increase, at the 90-day mark, in the number of participants showing a significant improvement of 2 points or more on the modified Rankin Score (mRS), a substantial reduction in the median score on the mRS, and a considerable decrease in the number of individuals displaying an improvement of 6 or more points on the NIHSS Level of Consciousness (1A)
In February 2022, Acticor Biotech disclosed encouraging results derived from its Phase Ib/IIa ACTIMIS clinical trial evaluating glenzocimab as an adjunctive therapy alongside the standard care for acute ischemic stroke (AIS) patients. The findings indicated the trial successfully achieved its primary objective by confirming the favorable safety profile of glenzocimab.
In February 2022, Bayer revealed that the U.S. Food and Drug Administration (FDA) has provided Fast Track Designation for its experimental drug asundexian (BAY2433334) concerning its potential application as a treatment for secondary prevention among patients who have experienced a non-cardioembolic ischemic stroke.
In May 2022, Athersys, Inc. disclosed that its collaborator, HEALIOS K.K. (Healios), released the key findings from its Japan-based ischemic stroke study, TREASURE. The study revealed notable improvements in predetermined functional measures associated with “independence” and positive outcomes such as mRS ≤2, Barthel Index ≥95, and Global Recovery linked to MultiStem treatment. However, the primary endpoint of achieving an excellent outcome at 90 days did not demonstrate statistical significance in the overall population. Importantly, there were no substantial differences observed in safety outcomes, including mortality and life-threatening adverse events, between the treatment and placebo groups.

Ischemic Stroke Overview

An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.

Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

Microlyse: TargED Biopharmaceuticals
ST-01: Saillant Therapeutics
Elezanumab: AbbVie
RNS60: Revalesio Corporation
BIIB131: Biogen
Glenzocimab: Acticor Biotech
3K3A-APC: ZZ Biotech
Nelonemdaz: GNT Pharma
MultiStem: Athersys, Inc.
Glenzocimab: Acticor Biotech
Elezanumab: AbbVie
LT3001: Lumosa Therapeutics
AVLX-144: Avilex Pharma

Ischemic Stroke Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Ischemic Stroke Molecule Type

Ischemic Stroke Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Ischemic Stroke Pipeline Therapeutics Assessment

Ischemic Stroke Assessment by Product Type
Ischemic Stroke By Stage and Product Type
Ischemic Stroke Assessment by Route of Administration
Ischemic Stroke By Stage and Route of Administration
Ischemic Stroke Assessment by Molecule Type
Ischemic Stroke by Stage and Molecule Type

DelveInsight’s Ischemic Stroke Report covers around 55+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies

Some of the key companies in the Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Ischemic Stroke are – Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

Ischemic Stroke Pipeline Analysis:

The Ischemic Stroke pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies

Ischemic Stroke Pipeline Market Drivers

Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.

Ischemic Stroke Pipeline Market Barriers

However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.

Scope of Ischemic Stroke Pipeline Drug Insight

Coverage: Global
Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others
Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others
Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers

Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials

Table of Contents

1. Ischemic Stroke Report Introduction

2. Ischemic Stroke Executive Summary

3. Ischemic Stroke Overview

4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5. Ischemic Stroke Pipeline Therapeutics

6. Ischemic Stroke Late Stage Products (Phase II/III)

7. Ischemic Stroke Mid Stage Products (Phase II)

8. Ischemic Stroke Early Stage Products (Phase I)

9. Ischemic Stroke Preclinical Stage Products

10. Ischemic Stroke Therapeutics Assessment

11. Ischemic Stroke Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ischemic Stroke Key Companies

14. Ischemic Stroke Key Products

15. Ischemic Stroke Unmet Needs

16 . Ischemic Stroke Market Drivers and Barriers

17. Ischemic Stroke Future Perspectives and Conclusion

18. Ischemic Stroke Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Biogen, Athersys, Inc., Tarveda Therapeutics

The Blue Light Glasses Protect Eyes from the Impact of the Screen World

“At Vooglam, we believe that every pair of glasses is more than just an accessory. It is an extension of your personality and your window to the world. No matter who you are or where you are, this Halloween, let Vooglam be with you Reveal your true self.”

Explore the world of blue light blocking glasses with Vooglam. Learn how these innovative lenses protect your eyes from digital strain, enhance sleep patterns, and fit your style. Vooglam combines health and fashion in eyewear, offering affordable, high-quality blue light filtering glasses. Perfect for office workers, gamers, and digital device users.

For office workers, spending approximately 1,700 hours per year immersed in electronic screens has become the norm. We often find ourselves engrossed in digital device screens for hours on end, whether it’s checking early morning emails or indulging in a late-night Netflix binge. The next exciting post on Instagram or the next entertaining video on TikTok is always just a click away. But have you ever considered the long-term effects of prolonged exposure to blue light on your eyes and overall health?

Doctors and researchers have provided a clear and concise answer to this question, which is of primary concern to many: prolonged exposure to a blue light environment poses the risk of digital eye strain.

What is blue light, and how does it affect us?

The visible light spectrum consists of light waves ranging from red to purple, and among these waves is blue light. Evidence suggests that blue light is associated with various issues, from eye strain to even blindness. In fact, most electronic screens, including those of our beloved devices, are equipped with LED screens that emit high-energy, short-wavelength blue light, which can have adverse effects on our health. Quoting the American Optometric Association, they state, “Digital eye strain is a group of vision-related problems resulting from the prolonged use of computers, tablets, e-readers, and cell phones. These problems can include, but are not limited to, blurred vision, dry eyes, headaches, and even neck pain.” Especially concerning is the blue light emitted in low-light or dark conditions, which can disrupt sleep patterns and potentially harm the retina. This provides a compelling reason to study how to avoid and minimize the interference of blue light in our lives and health.

After scientists and the general public became aware of the potential hazards of blue light, a product emerged to combat its effects on individuals—blue light blocking glasses. This remarkable product, professionally designed, has the ability to filter out most harmful blue light emitted from electronic device screens, providing an extra layer of protection for your eyes. Imagine being able to enjoy your favorite content without worrying about eye fatigue or disruptions to your sleep patterns. The advent of blue light blocking glasses has made all of this possible.

How do blue light blocking glasses work, and why are they effective?

Serving as a barrier between your eyes and electronic screens, they employ special coatings to reflect and filter the harmful effects of blue light, protecting your eyes from the direct impact and reducing eye fatigue. By minimizing the blue light that reaches your eyes directly, these lenses offer protection for virtually everyone, whether you’re a student burning the midnight oil, a parent catching up on emails after the kids are in bed, or an avid enthusiast of video games and various series.

Before choosing blue light-blocking glasses, consider whether you can control your screen usage to mitigate the potential health risks associated with blue light exposure. For most people, the answer is clear – it’s time to consider a pair of blue light-blocking glasses to protect yourself.

If you’re in need of blue light-blocking glasses for immediate protection, we recommend an excellent and cost-effective brand – Vooglam. Vooglam is a beloved and trusted brand in the eyewear industry, with a strong focus on eye health. Their products are durable, flexible, and comfortable. As a brand with a mature and professional online sales channel, you won’t need to go through complicated steps to customize your blue light lenses – everything you need is at your fingertips.

Whether you order from their website or app, simply select “Blue Light Blocking” in the lens options during the ordering process. Vooglam’s blue light-blocking lenses are compatible with prescription glasses as well as fashionable styles for those looking to change their look. While many eyewear companies offer blue light-blocking lens options in their fitting choices, Vooglam stands out for its exceptional quality and reputation. Additionally, Vooglam provides hundreds of budget-friendly, high-quality choices. As a leading brand in fashion frames, their TAGs always lead the way in the next fashion trend on social media.

Concerned that your frame won’t suit you?

As a recommended brand that deeply considers its customers, Vooglam has introduced an AR try-on feature on its app. With just a camera-equipped smartphone, you can try hundreds of different styles of glasses. These unique frames suit all face shapes. Why spend money on ordering glasses online without trying them first? Consider Vooglam’s AR try-on solution to select the perfect glasses for you.

A Wise Shopping Choice:

Generally, blue light-blocking lenses tend to be more expensive than regular lens materials due to their unique advantages and specialized functionality. However, Vooglam’s promotional activities make these professional lenses more affordable. No matter where you come across this promotion, you shouldn’t miss out on this fantastic buying opportunity.

You can find options for anti-blue light prescription lenses on Vooglam’s eyewear details online shop page. If you are already a Vooglam customer or have received information notifications from Vooglam, just click on the latest promotion link to view the details. It’s never too late to take care of your eye health. Vooglam’s cost-effective anti-blue light lenses protect your eye health.

Media Contact
Company Name: Vooglam
Contact Person: Byron
Email: Send Email
Phone: +13023097808
Address:5900 BALCONES DRIVE SUITE 100
City: Austin
State: Texas
Country: United States
Website: https://www.vooglam.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Blue Light Glasses Protect Eyes from the Impact of the Screen World

AV Access Introduces iDock C10 KVM Switch Docking Station, Empowering Users to Create a Dynamic Home Workstation

“AV Access introduces the iDock C10 4K KVM switch docking station to cater to the growing number of individuals working from home. As the demand for multiple PCs and monitors rises, this innovative device enables users to effortlessly manage two PCs, two 4K monitors, and numerous peripherals simultaneously.”

AV Access presents the iDock C10, a groundbreaking integration of a dual monitor KVM switch and a 12-in-1 docking station. This innovative device allows users to effortlessly control their desktop or laptop with two monitors and multiple peripherals, enhancing productivity in office work, learning, and gaming.

AV Access, a leading provider of Pro AV and AV over IP solutions, is excited to unveil the iDock C10 KVM switch docking station as the latest addition to its impressive lineup of KVM switches. With its dual monitor design, extensive peripheral connectivity, full-featured USB-C input port, remarkable ultra-high refresh rates, and other exceptional features, iDock C10 is the perfect solution for office work, gaming, and learning.

4K Dual Monitor KVM Switch with a Versatile 12-in-1 Docking Station

“Today, an increasing number of individuals working from home find themselves in need of multiple PCs and monitors, as well as various peripheral devices such as keyboards, microphones, and SD cards. Our new KVM switch docking station is specifically tailored to meet the requirements of these professionals, including video editors, graphic designers, and avid gamers. It simplifies home office setups, reduces the need for additional peripherals, and significantly enhances productivity,” explained Bill Liao, CTO of AV Access.

The iDock C10 4K dual monitor KVM switch features a USB-C input port (supporting multi-stream transport) for a laptop, along with an integrated HDMI + DisplayPort + USB-B input port for a desktop computer. Furthermore, users can take advantage of abundant peripheral connectivity, including 3x USB 3.0, 2x USB 2.0, 1x USB-C, 1x SD card, 1x LAN, 1x Toslink out, 1x 3.5mm headset, and two HDMI outputs, allowing seamless integration of multiple devices.

Immersive High Refresh Rate & Fast Switching

The iDock C10 KVM switch supports ultra-high refresh rates, such as 1080P@240Hz/165Hz/144Hz/120Hz and 2560×1440@144Hz/120Hz, ensuring smooth switching between high-speed racing game sources.

Moreover, equipped with a full-featured USB-C port, this powerful 4K KVM switch offers users the ability to transfer data, audio, video, and power using just a single USB-C cable. Dual 4K UHD videos can be inputted, enabling the transmission of large data volumes at up to 5Gbp/s while simultaneously charging the laptop with up to 60W.

Switching between two PC sources is effortless and swift, thanks to the automatic PC wake-up and EDID emulation features of the 4K KVM switch. Users can effortlessly switch between their devices in just 2-3 seconds.

“Our highly sought-after KVM switch docking station is now available for purchase on our official site at the competitive price of $259.99. It is an essential tool for seamlessly switching between your gaming PC and workstation,” added Bill.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP products, which include extenders, splitters, switchers, matrixes, AV over IP codecs, etc. Since establishment, it has long been our mission to offer ultimate audiovisual experience to the masses by delivering quality-assured and well-designed AV products at honest pricing. We will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access be qualified as your faithful partner! Learn more by visiting www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Introduces iDock C10 KVM Switch Docking Station, Empowering Users to Create a Dynamic Home Workstation

Balance7: Bringing Hope and Relief to Those Undergoing Chemotherapy This Holiday Season

Balance7 is generously donating 100 gallons of their acclaimed product to those grappling with the side effects of chemotherapy treatments.

In a heartwarming initiative this holiday season, Balance7, in collaboration with Al Siamon and Dr. Nooristani, is reaching out to support individuals undergoing the strenuous journey of chemotherapy. Committed to making a difference, Balance7 is generously donating 100 gallons of their acclaimed product to those grappling with the side effects of chemotherapy treatments.

“During the busy holiday period, it’s easy to overlook health, but it’s the most precious gift one can cherish,” remarks Dr. Nooristani, a respected internal medicine physician and the CEO of Balance7. He emphasizes the transformative impact of Balance7, a product designed to rejuvenate the immune system and help with chemotherapy side effects through its unique alkalinity-based formula.

This special initiative offers hope and much-needed relief to those facing the daunting journey of chemotherapy. Balance7’s success stories are not just claims but are echoed in the heartfelt testimonials of real individuals who have experienced significant improvements in their wellbeing. These inspiring stories of resilience and recovery are available for viewing at Balance7 Testimonials

The holiday season brings more than festive cheer; it brings an opportunity for a free trial of Balance7. However, availability is limited, and interested parties are encouraged to act swiftly to secure their place in this offer. The dedicated team at Balance7 is available from 7 am to 2 pm PST, Monday through Friday, to assist with the process. They can be reached at (800) 793-9039 for a chance to receive this holiday gift of health.

Balance7 is more than a product; it’s a commitment to enhancing the quality of life for those undergoing chemotherapy. While it’s not a cure, it empowers the body and the immune system to defend and recover, as highlighted by Al Siamon.

This season, Balance7 extends its hand in solidarity and support, offering a beacon of hope in the difficult journey of chemotherapy.

Contact: Balance7 Customer Support Phone: (800) 793-9039 Balance7 Official Website

Media Contact
Company Name: Balance7
Contact Person: Holly Davidson
Email: Send Email
Phone: (800) 793-9039
City: Santa Maria
State: CA
Country: United States
Website: www.balance7.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Balance7: Bringing Hope and Relief to Those Undergoing Chemotherapy This Holiday Season

5ire and GRO Initiative Form Strategic Partnership to Pioneer Sustainable Blockchain Solutions

In a stride towards combating global sustainability issues, 5ire, a dual-chain blockchain ecosystem focusing on in-consensus sustainability, has officially joined forces with GRO Initiative, a social-impact organisation dedicated to sustainable livelihood projects and reforestation. This strategic collaboration marks a commitment to become key innovators towards the UN Sustainable Development Goals (SDG) and the Digital Carbon Markets (DCM).

The collaboration between 5ire and GRO Initiative is a significant step beyond a mere alliance; it’s a shared vision to redefine the landscape of Digital Carbon Markets. Together, they aim to set new global standards within the carbon markets, establishing a practical benchmark for responsible and sustainable business practices.

Premium Carbon Offsets for a Greener Tomorrow

The partnership extends to the supply of 5ire’s Carbon Marketplace with GRO’s assets, injecting sustainability into the core of trading. This dynamic synergy ensures that every transaction contributes towards a greener and more sustainable future. Beyond short-term gains, the collaboration commits to a long-term wholesale supply of premium carbon offsets for the 5ire carbon market, making every user an active participant in global efforts to combat climate change.

Innovative RWA Solutions for a Carbon-Neutral World

The collaboration explores asset-backed carbon finance and investment solutions, propelling the financial sector into a new era of on-chain sustainable Real World Assets (RWA). This forward-thinking approach facilitates financial growth and contributes significantly to global efforts for a carbon-neutral future. 5ireChain, 5ire’s native blockchain platform, will provide greater liquidity to a highly fragmented voluntary carbon market, allowing companies to actively trade and retire carbon credits to offset emissions.

Shared Values, Common Goals

The collaboration extends beyond business, encompassing joint marketing, PR, and event strategies linking 5ire to GRO’s impact projects globally. This strategic alignment aims to create awareness and actively involve the community in the journey towards sustainable development.

At the core of this collaboration are shared values and common goals. Both 5ire and GRO Initiative are committed to fostering innovation to address the UN’s Sustainable Development Goals. This collaboration is a testament to their dedication to leveraging technology for positive environmental and social impacts.

About 5ire

5ire is a dual-chain (EVM and WASM) blockchain ecosystem that focuses on combatting global sustainability issues, aligning to the UN’s 2030 agenda for sustainable development. At the core of 5ireChain (5ire’s native blockchain) is a SPoS (Sustainable Proof-of-Stake) consensus mechanism that incentivises validators towards sustainability to receive higher rewards. 5ire aims to bring a paradigm shift from a for-profit to a for-benefit. 5ire’s goal is to combine blockchain with sustainability, whilst onboarding governments’, enterprises’ and institutions’ activities and reporting, related to sustainability-focused real-world assets (RWA).

About GRO Foundation

The GRO Foundation and its GRO Initiative is a social-impact organization dedicated to planting 1 billion trees and creating sustainable livelihood projects, connecting grassroots communities to the global carbon market.

For media inquiries, contact: press@5ire.org

Website: www.5ire.org

Media Contact
Company Name: 5IRE
Contact Person: Utkarsh Amitabh
Email: Send Email
Country: India
Website: www.5ire.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 5ire and GRO Initiative Form Strategic Partnership to Pioneer Sustainable Blockchain Solutions

Stallion Uranium (STLNF) Secures Key Permit for Groundbreaking Coffer Project in Saskatchewan’s Athabasca Basin

The uranium mining sector is poised for significant growth, driven by the global shift towards cleaner energy sources and nuclear power’s increasing role in this transition. Renewed interest in nuclear energy, fueled by environmental policies aimed at reducing carbon emissions and growing investments in nuclear technology, is placing uranium at the forefront. Additionally, geopolitical tensions and supply chain disruptions highlight the need for stable uranium supplies.

The sector’s growth is further bolstered by high-profile investments, such as the collaboration between Bill Gates and Warren Buffett to build a new nuclear reactor in Wyoming. This project, highlighting the interest of influential investors in nuclear energy, could further increase the demand for uranium, making uranium mining companies attractive for investors in the changing energy landscape.

One small cap company in the uranium mining sector that we would like to draw your attention to is Stallion Uranium Corp (TSX-V: STUD; OTCQB: STLNF; FSE: HM40).

Stallion Uranium (STUD) is working to Fuel the Future with Uranium through the exploration of over 3,000 sq/km in the Athabasca Basin, home to the largest high-grade uranium deposits in the world. The company holds the largest contiguous project in the Western Athabasca Basin adjacent to multiple high-grade discovery zones. The leadership and advisory teams at STUD are comprised of uranium and precious metals exploration experts with the capital markets experience and the technical talent for acquiring and exploring early-stage properties. Further, Stallion offers optionality with two gold projects in Idaho and Nevada that neighbour world class gold deposits offering exposure to upside potential from district advancement with limited capital expenditures.

In a recent press release, STUD announced it has received the necessary permits from the Saskatchewan Government to conduct ground-based geophysical surveys and diamond drilling exploration work on its 100% owned Coffer (“Coffer” or the “Project”) Uranium Project in the Athabasca Basin, Saskatchewan.

Highlights

The company is planning for a targeted ground geophysics survey to commence in the coming weeks that will further inform the planned maiden diamond drill program in Q1/2024.
Permitted activities include access trail construction, temporary camp establishment, geophysical surveying, and diamond drilling.
Permits are valid until Nov 1, 2026, allowing for multiple seasons of geophysical surveying and drill testing.

“We are thrilled to share the news that Stallion has secured an exploration permit for our Coffer project in the Athabasca Basin,” stated Drew Zimmerman, CEO of Stallion Uranium. “This permit represents a key step in our ability to continue to advance our high-potential uranium targets. The Southwestern Athabasca Basin is an underexplored corner of the globally recognized Athabasca Basin and we are eager to advance our exploration activities in this burgeoning region that holds the potential to host the next significant uranium discovery.”

Next Steps

Stallion will initiate a targeted geophysical survey in the coming weeks over the Appaloosa Target on the Coffer Project. Further information on the survey and target area will be released in the coming weeks.

About Coffer Project

The Coffer Project comprises 8 mineral claims and covering 35,875 hectares of highly prospective ground in the Western Athabasca Basin. The project has never been drill tested and contains several kilometer-scale prospective zones within the key target areas identified as Appaloosa, Clydesdale and Mustang. The Appaloosa target will be the focus of the up-coming exploration programs as the Company has identified gravity and magnetic lows on a conductive corridor known to correlate to alteration that hosts uranium mineralization. The highly prospective target area shares geological analogues to the nearby Shea Creek deposit, home to over 95M lbs. of uranium.

Stallion Uranium Corp. (STUD.V) has a 52 week high of 51 cents and if things go as planned for the company, Stallion Uranium Corp could exhibit a significant upside potential. As always, conduct your own due diligence and follow traders vigilance.

For more information, please visit https://stud.report/

Watch the below video for more information on STLNF/STUD.V

Video Link: https://www.youtube.com/embed/inyI4Osrm9A?si=dNt2LWC4wrkcZHf1

Some of other uranium mining stock to place on top of radar include Uranium Royalty Corp. (NASDAQ:UROY), Energy Fuels Inc. (NYSE:UUUU), Centrus Energy Corp. (NYSE:LEU), NuScale Power Corporation (NYSE:SMR), Ur-Energy Inc. (NYSE:URG), Denison Mines Corp. (NYSE:DNN), Sibanye Stillwater Limited (NASDAQ:SBSW), NexGen Energy Ltd. (NYSE:NXE), BHP Group Limited (NYSE:BHP), and Cameco Corporation (NYSE:CCJ).

Sources:

https://finance.yahoo.com/news/stallion-uranium-receives-exploration-permit-110000408.html

STUD

https://nypost.com/2021/06/04/bill-gates-warren-buffett-building-nuclear-reactor-in-wyoming/

Disclaimer: FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://JournalTranscript.com/disclaimer/. JournalTranscript.com has been compensated four thousand dollars by a 3rd party Khaos Media LLC for advertisement and content distribution services on STUD for 12/11/2023 to 12/31/2023. We own zero shares of STUD. JournalTranscript.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of JournalTranscript.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.JournalTranscript.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.JournalTranscript.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by JournalTranscript.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. JournalTranscript.com is not a fiduciary by virtue of any person’s use of or access to this content.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stallion Uranium (STLNF) Secures Key Permit for Groundbreaking Coffer Project in Saskatchewan\’s Athabasca Basin

Mangoceuticals, Inc. (MGRX) Expands Reach: Launches New Hair Growth Product ‘Grow’ and Strengthens Presence in Latin America with MangoRx Mexico

““This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MGRX Co-Founder and CEO. “First, ED medications…are available to consumers OTC in Mexico. That presents increased margin and sales volume potential for what we already produce and market here in the USA. Second, Mexico is a completely untapped market as our research indicates that we will be the only company offering an ED product in a flavored rapid-dissolve tablet…””

MangoRx (MGRX) is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of ED and hair growth

Mangoceuticals, Inc. (NASDAQ: MGRX), through its subsidiary MangoRx Mexico, is targeting the ED market in Mexico and Latin America, a region with an untapped potential for ED medications. This strategic move, facilitated by Diaz Reus International Law Firm, aims to leverage the over-the-counter availability of other ED drugs. With the introduction of their unique flavored rapid-dissolve tablet, MangoRx seems to be poised to capture a significant share of this market.

Manufacturing and Distribution: Laying the Foundation

The company’s focus now is on establishing strong manufacturing partnerships and gaining certification with COFEPRIS. These steps are crucial for securing a robust distribution network, aiming to reach over 40,000 pharmacies and retail outlets. This expansion is not a sudden pivot but a well-planned strategy, initiated in May 2023, to cement their presence in a market with a potential size of USD $216 million for ED pharmaceutical products.

International Recognition and Growth

Achieving COFEPRIS certification is not just a ticket to the Mexican market but also paves the way for expansion into other Latin American countries where ED medications are sold over the counter. This includes Columbia, Ecuador, El Salvador, Chile, Costa Rica, and Panama, significantly broadening MangoRx’s international footprint.

Innovative Partnership with TRYBE Labs

In a parallel strategic move, MangoRx has teamed up with TRYBE Labs to provide FDA-approved at-home blood collection devices and testing services. This collaboration aligns with the company’s commitment to innovative and convenient healthcare solutions, further enhancing its product lines that require physician-reviewed blood tests.

Affiliate Marketing and Consumer Empowerment

TRYBE Labs, with its focus on men’s health, also joins MangoRx as an affiliate marketing partner, aiming to boost the visibility and sales of MangoRx’s wellness products. This partnership emphasizes the importance of accessible healthcare and addresses the stigma often associated with men’s health issues.

Continued Expansion: MangoRx’s Product Line Diversification

Mangoceuticals, Inc. (MGRX) has further diversified its product line with the introduction of ‘Grow,’ a hair growth treatment. This addition complements their existing ED drug, ‘Mango.’ ‘Grow’ is a unique combination of Minoxidil, Finasteride, Vitamin D3, and Biotin, formulated into chewable, mint-flavored tablets. This innovative approach aligns with MangoRx’s philosophy of convenience and efficiency, avoiding the drawbacks of topical treatments.

Innovative Hair Growth Treatment: A Breakthrough in Men’s Wellness

The launch of ‘Grow’ marks a significant step in MangoRx’s mission to provide innovative health solutions. This custom-compounded treatment is designed to tackle male pattern baldness by promoting follicle development and preventing hair loss. The combination of clinically proven ingredients offers a promising solution for hair regrowth, emphasizing MangoRx’s commitment to evolving and performance-driven products.

Medical Endorsement and Clinical Efficacy

Dr. Douglas Christianson, ND, an advisory board member of MangoRx, endorses ‘Grow’ for its evidence-based approach to hair restoration. The product’s clinical efficacy in fostering hair regrowth and enhancing hair health makes it a medically sound choice for individuals addressing hair loss.

Addressing a Widespread Concern

With a significant portion of American men experiencing hair loss at an early age, ‘Grow’ responds to a widespread need for effective treatment. MangoRx’s telemedicine platform facilitates easy access to this treatment, with physician-reviewed prescriptions and discreet delivery.

MangoRx’s expansion into hair growth treatments, alongside its innovative ED products and strategic partnerships, showcases a holistic approach to men’s health and wellness. This comprehensive strategy, combined with their commitment to innovation and accessibility, positions MangoRx as a potential frontrunner in the healthcare sector. For traders and investors, MangoRx’s diverse product range and market expansion potentially represent a compelling opportunity for growth in the evolving healthcare market.

Watch the video below to learn more about MGRX:

Video Link: https://www.youtube.com/embed/lwVd2mKbG9s

MGRX is currently trading closer to its 52 week low (52 Week Range: $0.4200 – $4.3700). Considering the recent press releases and developments taking place at MGRX, there seems to be a significant upside potential for this NASDAQ stock. As always, conduct your own due diligence and follow traders vigilance.

In Monday morning’s session, several penny stocks showed notable activity. Sirius XM Holdings Inc. (SIRI) saw a 6.79% increase at $4.955 with 11.64M shares traded. Gaotu Techedu Inc. (GOTU) rose 7.79% to $2.975, with 5.52M shares changing hands. Innoviz Technologies Ltd. (INVZ) jumped 16.11% to $2.09 with a volume of 15.69M shares. Bluebird bio, Inc. (BLUE) increased by 8.70% to $3.1089, trading 21.55M shares. Meta Materials Inc. (MMAT) saw a smaller gain of 2.30% at $0.0668 with 7.07M shares traded. These movements highlight the dynamic nature of penny stocks in the market

Sources:

https://finance.yahoo.com/news/mangoceuticals-launches-mangorx-mexico-subsidiary-130000423.html

https://finance.yahoo.com/news/mangoceuticals-selects-trybe-labs-nationwide-133000517.html

https://finance.yahoo.com/news/mangoceuticals-expands-mens-health-product-133000245.html

https://www.businessresearchinsights.com/market-reports/hair-growth-treatment-product-market-103000

Disclaimer: FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated five thousand dollars by a 3rd party Bullzeyemedia LLC for advertisement and content distribution services on MGRX for 12/02/2023 to 12/31/2023. We own zero shares of MGRX. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mangoceuticals, Inc. (MGRX) Expands Reach: Launches New Hair Growth Product \’Grow\’ and Strengthens Presence in Latin America with MangoRx Mexico

Nano-Cap Notable News Watchlist (ORHB, BCNN, IFUS, DTGI)

In the quest for market catalysts, investors eye potential drivers of stock movements. Among these, news emerges as a formidable force, influencing prices and creating opportunities. Positive news, in particular, has the capability to propel stocks to new heights. Let’s explore four stocks with promising catalysts.

In a remarkable stride towards global expansion, HippoFi, Inc.(OTC: ORHB)‘s subsidiary, PUR Biologics, has made significant inroads into the international market, projecting sales to soar beyond $20 million in the upcoming year.

The biotechnology enterprise reached a new level of success with the breakthrough, which was announced in a press release on December 11, 2023. The breakthrough culminated in a year filled with remarkable accomplishments as the company successfully shipped products for use internationally. The company attributes this triumph to the concerted efforts of a robust distribution network comprising 250 distributors and over 300 sales representatives.

CJ Wiggins, Executive Chairman and CEO of HippoFi, acknowledged the dedication of the distribution network, underscoring the company’s exceptional growth over the last 12 months. “Combining our team of business and scientific experts, global partners, and best-in-class technologies with our world-class distribution network has established PUR as the ‘Authority in Spinal Biologics,'” remarked Wiggins.

The strategic move aligns with PUR Biologics’ aim to capitalize on the burgeoning market for spine surgeries utilizing biological implants, estimated to be worth $3.5 billion annually, with 1.62 million surgeries performed each year. Wiggins is optimistic about the company’s trajectory, expressing confidence in strong sales growth for 2024. “Our business is primed for strong sales growth in 2024 and is expected to track over $20 million,” he affirmed.

Wiggins highlighted the pivotal role of technology in their success, particularly the recent acquisition of the activeOrb technology from ZIMMER BIOMET. This strategic move positions HippoFi to secure a more substantial share of the $3.5 billion opportunity related to bone-growth solutions, further solidifying its standing in the dynamic healthcare market.

In conclusion, the recent international foray and optimistic projections underscore HippoFi’s commitment to pioneering biotech and AI technologies, enhancing patient outcomes, and positioning itself as a frontrunner in the ever-evolving landscape of healthcare innovation.

Balincan USA Inc. (OTC: BCNN), an alternative reporting publicly held company, witnessed an impressive 130% increase in its stock price on Monday. This surge coincides with the release of a significant press update providing insights into Balincan and Tekumo’s outstanding Q4 and 2023 milestones.

In the first two months of the quarter, the company reported a record-breaking revenue of $850K, showcasing a remarkable 516% growth over the corresponding period last year. This achievement surpasses the forecasted $5 million annualized run rate, highlighting the success of Tekumo as an industry-leading service delivery platform.

Phillip Dignan, President and CFO of Balincan, emphasized Tekumo’s pivotal role in reducing costs and time for customers through the management of onsite installation and maintenance of technology systems using on-demand local technicians. The financial update further revealed positive changes to the net loss to common shareholders and a reduction in derivative liability, showcasing the company’s commitment to financial transparency.

In addition to its financial successes, Balincan announced strategic corporate moves, filing for a name and symbol change to Tekumo, Inc. (TKMO), subject to FINRA approval. The filing of a Regulation 1-A offering statement with the SEC signals the company’s intent for follow-on financing to fuel continued growth. With the increase in authorized common shares to $5 billion, the company is strategically positioned for expansion.

In the realm of health and wellness, Impact Fusion International Inc. (OTC: IFUS) has emerged as a distinctive player, marketing proprietary products globally to promote well-being for humans and animals. Beyond the unconventional, the company’s recent updates underscore a proactive and impactful journey.

Impact Fusion International (OTC: IFUS) experienced a notable uptick on December 11, surging to 0.081 USD, reflecting a remarkable 17.05% increase. This surge aligns with IFUS’s strategic efforts in the “Health and Wellness” sector, where they aim to invent, develop, and market innovative products.

IFUS provided a thorough year-end update that detailed the company’s response to the drought conditions that have affected several southern states. IFUS introduced SGP+, an innovative solution with potential applications in enhancing herd health, reducing emissions, eliminating fly infestations, and cutting costs for ranchers. The company actively engages with government officials and key decision-makers to promote the adoption of their technology.

Recent achievements include securing orders from a large feedlot in East Texas and a dairy in Louisiana. According to CEO Marc Walther, a dedicated sales team has been appointed to represent IFUS at industry events and conventions. Furthermore, the company is exploring opportunities in India with positive conversations and a letter of intent from AgriGlow Biotech.

Impact Fusion obtained a USDA permit to import bagasse harvested in India for testing, with results expected in late February–early March 2024. A member of the team volunteers to relocate to India, emphasizing the team’s dedication to project success. Additionally, the company conducted an “Economic Viability Footprint” study, projecting potential replication in sugarcane-growing areas worldwide.

Digerati Technologies, Inc. (OTC: DTGI) recently reported robust financial results for the twelve months ended July 31, 2023, showcasing a significant growth trajectory. The company, specializing in Unified Communications as a Service (UCaaS) solutions for small to medium-sized businesses, experienced a 31% increase in revenue, reaching an impressive $31.6 million compared to $24.15 million in the prior year.

The key financial highlights include a 37% surge in gross profit to $20.34 million, resulting in an improved gross margin of 64.3% compared to 61.3%. Non-GAAP adjusted EBITDA income witnessed a remarkable 50% increase to $4.77 million, reflecting the company’s effective operational strategies and financial performance.

Digerati Technologies successfully streamlined its operations through the consolidation of subsidiaries into a single operating entity, Verve Cloud, Inc. This consolidation, coupled with the integration of acquisitions such as Skynet and NextLevel Internet, contributed to the significant growth in cloud software and service revenue.

Despite one-time, non-recurring costs of $2.55 million related to a terminated transaction with Minority Equal Opportunity Acquisition Corp., Digerati Technologies remains optimistic about its financial stability. The company continues to seek new strategic partnerships and complementary relationships, demonstrating its commitment to sustained growth.

The positive financial metrics, including increased revenue, gross profit, and adjusted EBITDA income, reflect the successful execution of Digerati Technologies’ business strategy. With a solid foundation in place, the company aims to capitalize on organic and inorganic growth opportunities in the cloud services market.

It’s essential to note that Digerati Technologies is actively pursuing strategic initiatives and looks forward to updating shareholders on its progress in the coming months. As the company serves nearly 4,700 business customers and approximately 50,000 users, predominantly in Florida, Texas, and California, it is well-positioned for continued success in the UCaaS sector

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by HippoFi Inc. to assist in the production and distribution of content related to ORHB. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nano-Cap Notable News Watchlist (ORHB, BCNN, IFUS, DTGI)

GPO Plus, Inc. Growth Pace Accelerates, Launches Mission To Expand Retail Presence In Eligible Yesway And Allsup Locations ($GPOX)

GPO Plus, Inc. (OTCQB: GPOX) stock may present a value investment opportunity that is too good to ignore. Yes, that’s a decidedly bullish sentiment. However, it’s supported by tangible evidence showing that GPOX continues to expand its revenue-generating footprint to make its retail presence more pronounced and, importantly, from a valuation perspective, can lead to another breaking of previously set performance records.

Contributing to that presumption is a deal made with hemp smokables company Hempacco Co, Inc. (NASDAQ: HPCO) that can expedite GPOX capitalizing on an estimated $1 trillion industry. And it’s expected to get even bigger, with consumer preference trends showing increasing interest in hemp-based products that offer a satisfying alternative to nicotine tobacco. The deal, which GPOX said will be facilitated through its distribution division Distro+, will promote, market, and sell Hempacco’s entire portfolio of hemp products in Yesway and Allsup’s stores across the United States. That’s no small opportunity.

Yesway is one of the fastest-growing convenience store operators in the United States. The better news is that the deal strengthens GPOX’s previously announced retail partnership, where it highlighted plans to introduce The Feel Good Shop+ in eligible Yesway and Allsup locations. The Feel Good Shop+ is an innovative “store within a store” retail concept offering an extensive range of CBD and other hemp-derived products. GPOX revenues could get a quick boost, especially with GPOX placing popular Hempacco products, including The Real Stuff Hemp Smokables, Rick Ross’s Hemp Hop Smokables and Wraps, Cheech & Chong Smokables and Wraps, and Snoops Dogg’s Dogg lbs brands.

Growth By The Numbers

If so, they will add to recent record-setting operating performance. GPOX announced the best-ever revenues in its 1Q for FY/2024 of $970,735, beating its forecast by roughly 12% and crushing the prior quarter’s revenues by 126%. That performance followed the over 320% sequential revenue growth. GPOX reporting FY/Q4 revenues of $430,000 represented an over 320% increase compared to the three months ending April 30, 2023. Revenues aren’t the only things getting larger.

The store count is as well. GPOX is now operating over 570 locations in several states, a number expected to increase to 1,000 by the end of its current fiscal year. There’s more good news. The average revenue contributions per location is surging, evidenced by the sales from the first 100 stores receiving the new “White Glove Direct Store Delivery” service offered through GPOX’s Distro+ division, soaring over 365% from $580 per location to $2,120. That growth is being met with a GPOX service model and infrastructure that is more efficient than ever, resulting from creating what the company calls a Mini-hub business model, a hub and spoke design that leverages low-cost efficiencies to generate high store revenues.

In particular, GPOX is realizing benefits through its mentioned “White Glove DSD,” a hands-on, full-service business model that GPOX said has been an integral part of driving average sales per unit to record levels. That makes sense. The hands-on service approach facilitates enhanced product offering and allows GPOX to maximize the intrinsic value of its in-store concept, “the Feel Good Shop+,” which offers customers CBD-inspired health and wellness products. Moreover, the GPOX team presence is leading to a potential windfall of revenue-generating opportunities by being on-site to provide clients with a service and benefit that others don’t- primarily filling a product manufacturing and delivery gap for the 15% – 20% of items not typically provided by primary vendors. Technology enhancements are fueling the back end of that opportunity.

GPOX announced live testing, implementation, and the rollout phase for MSRP+, its proprietary software empowering order management, logistics optimization, lead generation, sales analytics, accounting, inventory management, and e-commerce for DISTRO+. Those enable a strategy that maximizes intrinsic strengths, particularly those related to manufacturing and distributing consumer products, fitting well into the GPOX strategy to increase convenience store and specialty retailer client count.

Attracting Clients Through Service

So far, GPOX has said that the service is leading many of its retail partners to ask what additional products can be provided through this uncomplicated and comprehensive GPOX service solution. That’s helped GPOX model for significant near-term growth, saying its combined service differences should contribute to opening at least 500 new locations in its fiscal year. Even better from an investor’s perspective is that by utilizing proprietary technology, real-time data, and efficiencies from its hub and spoke business services model, GPOX revenues from new and existing sites could fall faster toward the bottom line. And there could be plenty more of it to drop.

GPOX believes increased product offerings could increase average sales per convenience store location to over $3,000, about 40% higher than current. Contributing to that cause, GPOX highlighted executing its plans to introduce proprietary new products, such as Yuenglings Ice Cream flavored gummies and High-Cloud gummies, expected to generate roughly 40% gross margins. The gross margins for general products are also impressive, typically between 20% – 35%. Strength in both should accelerate GPOX reaching cash-flow and/or bottom-line EPS, potentially by the end of this new fiscal year. They should get additional help.

GPOX said it expects to onboard roughly 258 new locations in Texas, Iowa, and Kansas by the end of this year and another 123 locations throughout New Mexico in early 2024. With plans to serve the entire product line at each site, using a store-average sales estimate should add appreciably to near-term revenue streams. It could increase further from its mission to fill a service gap. According to GPOX, most retailers get about 80% – 85% of their products from just a few distributors, with the remaining products sometimes represented by dozens of separate vendors.

As one might expect, that’s a significant pain point for most corporate retailers, especially gas stations and convenience stores that sell potentially thousands of different products. For management, it’s a tall order to handle. It’s where GPOX intends to shine by using its White Glove DSD service to mitigate specialty retailers’ challenges of identifying and qualifying new products, ensuring quality, and managing delivery. In the best case, GPOX believes its White Glove DSD service can help to eliminate 100% of the challenges faced, a stat that is doing more than attracting new business; it’s contributing enormously to the growth of serviced locations by simplifying and optimizing client operations.

A Growth Mission In Progress

That could lead to an already impressive growth trajectory to steepen. That’s likely from GPOX’s offering to do the heavy lifting for clients, including price negotiation, meeting minimum order requirements from large manufacturers, and providing uncompromising, hands-on service, from order placement to shelf stocking to end-sales management. Recent quarterly performance shows that that strategy is shifting GPOX’s growth pace from hyperspeed to warp.

The only thing lacking, which is not necessarily bad for investors since it exposes opportunity, is for the share price to follow that lead. By all measures, they should. GPOX is posting consecutive record-setting operating performance, is appreciably growing its retail presence with top-tier clients, and has simplified operations to make revenues more impactful to its bottom line.

In other words, the disconnect between the GPOX share price and the groundwork laid, completed, and pending may be worth seizing. In fact, with GPOX better positioned today than when it scored its 52-week high of $0.29, about 81% higher than current, doing so sooner rather than later may be the best course of action.

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of GPO Plus, Inc. (Nasdaq: GPOX). Primetime Profiles Direct, a property of Shore Thing Media Group, Llc. is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Shore Thing Media Group, Llc. was retained by Spyder Growth Strategies, Llc to create and distribute digital content for GPO Plus, Inc. Spyder Growth Strategies Llc compensated Shore Thing Media Group, Llc., and/or, its parent company, $5,000 to complete and distribute these services. This advertisement is being disseminated for a period of one month beginning on 12/4/23 and ending on 12/31/23. Shore Thing Media Group, Llc. owners, officers, principals, affiliates, contributors, and/or related parties do not own, intend to own, sell, or intend to sell GPO Plus, Inc. stock. However, it is prudent to expect that those hiring Shore Thing Media Group, Llc, including its owners, employees, and affiliates may sell some or even all of the GPO Plus, Inc. shares that they own, if any, during and/or after this engagement period. If successful, this advertisement will increase investor and market awareness of GPO Plus, Inc. and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement does not purport to provide a complete analysis of GPO Plus, Inc. or its financial position. The agency providing this content are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about GPO Plus, Inc. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in GPO Plus, Inc. SEC filings. Investing in microcap securities such as GPO Plus, Inc. is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, Shore Thing Media Group, Llc. cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of GPO Plus, Inc. and/or its industry. Shore Thing Media Group, Llc. note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect GPO Plus, Inc. actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for GPO Plus, Inc. products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. Shore Thing Media Group, Llc. are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks. Additional disclosures and disclosures can be found at https://primetimeprofiles.com/disclaimer/.

Media Contact
Company Name: STM, LLC.
Contact Person: Michael Thomas
Email: contact@primetimeprofiles.com
Country: United States
Website: https://primetimeprofiles.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GPO Plus, Inc. Growth Pace Accelerates, Launches Mission To Expand Retail Presence In Eligible Yesway And Allsup Locations ($GPOX)

Silanes Market Forecasted to Reach USD 3.9 Billion by 2027, at a CAGR of 6.2%

“Browse 286 market data Tables and 50 Figures spread through 284 Pages and in-depth TOC on “Silanes Market””

Silanes Market by Type (Functional Silanes, Mono/Chloro Silanes), Application (Rubber & Plastics, Fiber Treatment, Adhesive & Sealants), End-Use (Building & Construction, Electrical & Electronics, Automotive), And Region

The global Silanes market size is approximated to be USD 2.9 billion in 2022, and it is projected to reach USD 3.9 billion by 2027 at a CAGR of 6.2%. Silanes, also known as silicon hydrides, are compounds formed by covalent bonds between hydrogen and silica. Silanes are manufactured by reacting magnesium silicide with acids or by reducing silicon chlorides with lithium aluminum hydride. Silanes mainly function as coupling agents and surface modifiers. They are available in two types: functional and non-functional groups. The ability of functional silanes to react with inorganic and organic materials and that of non-functional with inorganic materials makes them useful in applications such as crosslinking agents, adhesion promoters, surface modifiers, coupling agents, and dispersing agents. Silanes act as an important part of the rubber & plastics sector, especially the tire industry. The major applications of silanes also include fiber treatment, adhesives & sealants, and paints & coatings.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=202415042

The demand for silanes is mainly furnished by three major sectors that is rubber & plastics, fiber treatment and adhesive & sealants. Some of the leading companies involved in the manufacturing of silanes are Evonik Industries (Germany), Shin-Etsu Chemical Co. Ltd (Japan), Momentive Performance Materials Holdings LLC (US), Dow Inc. (US), Wacker Chemie AG (Germany), Gelest Inc. (US), China National BlueStar (Group) Co. Ltd. (China), WD Silicone Co. Ltd. (China), Jingzhou Jianghan Fine Chemical Co. Ltd. (China), and Nanjing Shuguang Chemical Group Co. Ltd. (China).

Evonik Industries (Germany), deals in various segments, such as smart materials, specialty additives, nutrition & care, performance materials, and technology & infrastructure. The company’s smart materials has covered the largest market share. The company manufactures and sells silanes through the smart materials business segment. The company’s inorganic materials & coatings business unit manufactures silanes and serves various end-use industries such as electronics, construction, tire, and fiber optics.

Shin-Etsu Chemical Co. Ltd (Japan), operates through four business segments — infrastructure materials, electronics materials, functional materials, and processing & specialized services. The company manufactures silanes through the functional materials segment. Functional materials segment. Company manufacture silanes, which find use in a wide range of applications, ranging from thermosetting resins, primers, and paints to electronics and resin modifiers. It has a presence in Japan, Europe, Asia-Pacific, South America, and North America.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=202415042

Momentive Performance Materials Holdings LLC (US), engages in the production and commercialization of silanes. It operates business through two subsidiaries, namely, Momentive Specialty Chemicals and Momentive Performance Materials Inc. The company develops and manufactures silicones, ceramic materials, and fused quartz. The company offers silanes, specialty silicones, and urethane additives to serve end-use industries such as building & construction, automotive, aerospace, electronics, and medical.

Read Our Trending Press Release Below:

Flow Chemistry Market– Global Forecast to 2028

Electrical Conduit Market – Global Forecast to 2026

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/silanes-market-202415042.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Silanes Market Forecasted to Reach USD 3.9 Billion by 2027, at a CAGR of 6.2%